Treatment with interferon alpha prior to discontinuation of imatinib in patients with chronic myeloid leukemia.
暂无分享,去创建一个
Arnon Nagler | Ninette Amariglio | A. Nagler | L. Trakhtenbrot | N. Amariglio | A. Shimoni | Luba Trakhtenbrot | Avichai Shimoni | I. Hardan | Maya Koren-Michowitz | Izhar Hardan | Anfisa Stanevsky | Yuliya Volchek | Tali Tohami | A. Stanevsky | T. Tohami | M. Koren-Michowitz | Yu. A. Volchek
[1] J. Cayuela,et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. , 2005, Blood.
[2] Yoo-Jin Kim,et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy , 2009, Leukemia & lymphoma.
[3] Arnon Nagler,et al. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. , 2011, Blood.
[4] P. Cony-Makhoul,et al. Interferon Alpha Alone Is Able to Cure Chronic Myeloid Leukemia In a Small Subset of Patients Despite the Persistence of Leukemic Cells: Experience of Long Follow up After Treatment Discontinuation , 2010 .
[5] Manuel Ayala,et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. , 2010, The New England journal of medicine.
[6] T. Tauchi,et al. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. , 2009, Leukemia research.
[7] K. Rezvani,et al. Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. , 2010, Blood.
[8] Susan Branford,et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.
[9] Simona Soverini,et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.
[10] Z. Rudzki,et al. BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria , 2007, Clinical Cancer Research.
[11] H. Mano,et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. , 2001, Blood.
[12] C. Barthe,et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Andreas Trumpp,et al. IFNα activates dormant haematopoietic stem cells in vivo , 2009, Nature.
[14] Philippe Rousselot,et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.
[15] H. Kantarjian,et al. Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis , 2003, Cancer.
[16] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[17] I. Flinn,et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. , 2011, The Lancet. Oncology.
[18] F. Giles,et al. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia , 2009, Leukemia.
[19] Andreas Neubauer,et al. Interferon a and T-cell responses in chronic myeloid leukemia , 2005 .
[20] A. Nagler,et al. Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha 2a. , 1994, Journal of hematotherapy.
[21] M. Gasparetto,et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies , 2007, Leukemia.
[22] Ricardo Pasquini,et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. , 2010, The New England journal of medicine.
[23] Martin C. Müller,et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Mark M. Davis,et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia , 2000, Nature Medicine.